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Acyclovir suppressive therapy (400 mg twice daily) reduces
herpes simplex virus (HSV) type 2–associated genital ulcer
disease and lesional HSV shedding. In an international trial
of acyclovir for suppression of HSV type 2 to prevent human
immunodeficiency virus (HIV) acquisition (HIV Prevention
Trials Network 039), acyclovir had a smaller effect on the
frequency of genital ulcer disease as well as a smaller effect
on the frequency and quantity of lesional HSV DNA in Af-
rican women and Peruvian men, compared with its effects
in men in the United States. The observed regional varia-
tion in the clinical and virologic efficacy of acyclovir for
HSV suppression warrants further evaluation of determi-
nants of responses to acyclovir. (ClinicalTrials.gov identifier:
NCT00076232.)
Herpes simplex virus type 2 (HSV-2) is the most common
etiology of genital ulcer disease (GUD) worldwide and has been
associated with a 2–4-fold increase in acquisition of human
immunodeficiency virus (HIV) [1]. It is hypothesized that in-
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creased HIV acquisition risk is conferred by breaches in genital
epithelium, as well as genital inflammation during reactivation
of herpes simplex virus (HSV). Herpetic ulcerations compro-
mise the integrity of genital epithelium and mucosa and recruit
activated CD4+ and CD8+ T lymphocytes and dendritic cells
that may facilitate HIV attachment and infection during sexual
intercourse [2].
We recently completed a randomized placebo-controlled tri-
al (HIV Prevention Trials Network [HPTN] 039) to evaluate
whether 400 mg of acyclovir twice daily could reduce HIV ac-
quisition among 3172 HSV-2–seropositive men who have sex
with men (MSM) in the United States and Peru and women
in sub-Saharan Africa by suppressing HSV [3]. This trial failed
to demonstrate a protective effect of this regimen on the in-
cidence of HIV acquisition, confirming the results of another
trial that tested the same intervention in Tanzanian women [4].
As a secondary objective, HPTN 039 evaluated the impact of
acyclovir on symptomatic genital ulcers, as well as on virologic
end points, defined by the frequency and amount of HSV de-
tected in genital ulcers that are observed on examination. The
efficacy of acyclovir has been extensively characterized in de-
veloped countries; however, there is a paucity of data on acy-
clovir efficacy in resource-poor countries. Although acyclovir
has now been added to the World Health Organization list of
essential drugs, many sexually transmitted disease treatment
clinics in Africa still do not have access to the drug, and the
cost of the medication limits its use. In addition, evaluation of
acyclovir in resource-poor settings has focused on treatment
of GUD and not on prevention of HSV reactivation. Thus, our
trial provides novel information about the clinical and virologic
efficacy of suppressive acyclovir in resource-poor settings.
Methods. A total of 3127 evaluable HIV-negative, HSV-2–
antibody–positive participants were enrolled into the HPTN
039 trial. MSM were enrolled at sites in the United States (Se-
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attle, WA; San Francisco, CA; and New York, NY) and Peru
(Lima, Iquitos, and Pucallpa), and women were enrolled at
sites in Harare, Zimbabwe; Lusaka, Zambia; and Johannesburg,
South Africa. Informed consent was obtained from study par-
ticipants, and institutional review boards approved the protocol
at each participating trial site. Eligibility criteria and screening
procedures are described in further detail elsewhere [3].
Participants were randomized to receive 400 mg of acyclovir
or a matching placebo twice daily and were seen monthly for
12–18 months. During monthly visits, participants were asked
about symptoms of genital herpes in the past 7 days. Clinicians
performed a genital examination at all quarterly study visits
and at any monthly or interim study visit if symptoms of genital
ulcers were reported. The study staff obtained swab specimens
from lesions clinically consistent with a herpes recurrence; swab
specimens were placed into polymerase chain reaction (PCR)
medium, frozen, and shipped to the virology laboratory at the
University of Washington. An HSV DNA PCR assay was per-
formed according to validated, previously published proce-
dures [5, 6]. Samples were analyzed using a real-time fluores-
cent probe–based PCR assay (TaqMan; Applied Biosystems) to
quantitate HSV, and results were considered positive for HSV-
2 if 13 copies/reaction, or 150 copies/mL of fluid, were detected
[7]. Means, medians, and standard deviations of HSV-2 DNA
copy counts from genital ulcer specimens were calculated by
study arm, and the distribution for log10 HSV PCR titer was
plotted by study arm and region. Monthly and quarterly rates
of adherence to the study drug regimen were computed on the
basis of monthly pill counts from returned study drug bottles
and self-reports. Because each participant provided swab sam-
ples at up to 6 different study visits, we used generalized es-
timated equations to analyze numbers of cases of GUD, HSV-
2 positivity from lesional swab specimens, and mean log10 HSV
copy counts. Models for mean reduction in HSV were adjust-
ed for age and report of genital ulcers in the 3 months prior
to enrollment. To explore whether reductions in HSV shed-
ding were affected by adherence to the study drug, analyses
were stratified by adherence level as measured by monthly pill
counts averaged for the preceding quarter (90% and 190%).
For counts (ie, numbers of cases of GUD) and binary results
(HSV-2 positivity), a log link and negative binomial distribution
was used. For continuous outcomes (ie, log10 HSV DNA copy
counts), an identity link and normal distribution was used. An
independence working correlation and a robust covariance es-
timate were used in all analyses.
Results. A total of 459 MSM were enrolled at US sites, a
total of 1355 MSM were enrolled at Peruvian sites, and a total
of 1358 women were enrolled at African sites. At baseline, 131
(29%) of the US MSM and 227 (17%) of the Peruvian MSM
reported having had anogenital herpes symptoms over the prior
3 months; 3% of men from each region received a clinical
diagnosis of GUD at enrollment. In contrast, 443 (33%) of the
women reported symptoms over this time period and 225
(17%) received a diagnosis of GUD on examination. During
the 18-month study follow-up period, 915 (29%) of the 3172
total participants received a diagnosis of GUD on examination,
for a total of 1664 episodes detected. The GUD incidence varied
by study arm and population. The overall rate of GUD diag-
nosis on examination was 55 cases per 100 person-years in the
placebo group compared with 30 cases per 100 person-years
in the acyclovir group ( ). For the US MSM, the rate ofP ! .001
GUD was 53 cases per 100 person-years in the placebo group,
compared with 15 cases per 100 person-years in the acyclovir
group. For the Peruvian MSM, the rate of GUD was 34 cases
per 100 person-years in the placebo group compared with 16
cases per 100 person-years in the acyclovir group. For the Af-
rican women, the rate of GUD was 75 cases per 100 person-
years in the placebo group, compared with 46 cases per 100
person-years in the acyclovir group. Overall, acyclovir was as-
sociated with a 47% reduction in the incidence of GUD (relative
risk [RR], 0.53 [95% confidence interval {CI}, 0.46–0.62]); the
associated reduction was 71% in US MSM (RR, 0.29 [95% CI,
0.18–0.47]), but it was only 53% in Peruvian MSM (RR, 0.47
[95% CI, 0.36–0.62]) and 39% in African women (RR, 0.61
[95% CI, 0.51–0.74]; for the difference in treatmentP ! .001
effect by region). Thus, we observed statistically significant re-
gional variation in the proportional reduction in the incidence
of GUD with acyclovir suppression.
To explore these differences, we examined virologic data ob-
tained from 1468 swab specimens collected from participants
with GUD. Overall, 861 (59%) of the 1468 swab specimens
tested positive for HSV-2 (630 of 962 in the placebo arm com-
pared with 231 of 506 in the acyclovir arm; ). ThisP ! .001
represented a 63% reduction in the incidence of ulcers with
detectable HSV-2, although regional differences persisted. We
found an 88% reduction in the incidence of HSV-2–positive
breakthrough genital ulcers among enrolled US MSM (97 of
137 in the placebo arm compared with 12 of 43 in the acyclovir
arm; RR, 0.12 [95% CI, 0.05–0.29]), but only a 61% reduction
in Peruvian MSM (185 of 261 in the placebo arm compared
with 71 of 121 in the acyclovir arm; RR, 0.39 [95% CI, 0.28–
0.56]), and a 57% reduction in African women (348 of 564 in
the placebo arm compared with 148 of 342 in the acyclovir
arm; RR, 0.43 [95% CI, 0.34–0.56]; for the differenceP ! .001
in RR between regions). Of the samples with detectable HSV,
the mean HSV-2 DNA copy number detected in lesions was
reduced by 0.43 log10. However, as shown in Figure 1, the re-
duction was highest among US MSM: there was an observed
1.07 log10 reduction with acyclovir (95% CI, 0.33–1.80 log10
copies; ) among US MSM, a 0.68 log reduction (95%Pp .004
CI, 0.04–1.32 log10 copies; ) among Peruvian MSM, andPp .04
only a 0.32 log10 reduction (95% CI, 0.01–0.63 log10 copies;
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Figure 1. Comparison of herpes simplex virus (HSV) DNA copy counts in 861 swab specimens with detectable HSV from genital ulcers, by study
arm and by region. The number of swab specimens (N) and the mean, median, and standard deviation (SD) of the HSV DNA log10 copy count is
provided for participants randomized to receive placebo (left) or acyclovir (right).
Table 1. Reductions in Herpes Simplex Virus (HSV) DNA Copy Count in Patients Who Received Acyclovir, Compared with
Patients Who Received Placebo, by Region
Variable
No. of
swab
specimens
Mean reduction in log10 copy count (95% CI)
Overall
P for
overall valuea US MSM Peruvian MSM African women
Unadjusted 861 0.43 (0.15–0.71) .003 1.07 (0.33–1.80) 0.68 (0.04–1.32) 0.32 (0.01–0.63)
Adjustedb 861 0.46 (0.18–0.75) .001 1.12 (0.40–1.84) 0.70 (0.05–1.34) 0.32 (0.01–0.64)
190% Adherencec 627 0.57 (0.25–0.89) .001 1.31 (0.20–2.42) 0.89 (0.15–1.63) 0.47 (0.11–0.83)
NOTE. Patients were HSV-positive patients with genital ulcer disease (GUD). CI, confidence interval; MSM, men who have sex with men.
a P value for overall reduction associated with acyclovir compared with that associated with placebo.
b Generalized estimated equation multivariate analysis adjusted for age and baseline report of GUD symptoms in the 3 months prior to enrollment.
c Unadjusted analysis restricted to swab specimens collected from MSM and women with 190% average quarterly adherence to the study
drug regimen, as measured by monthly pill count.
) among the African women ( for the differencePp .05 Pp .13
between regions). As shown in Table 1, these estimates were
minimally affected when adjusted for age and reported history
of GUD in the 3 months prior to enrollment. In an unadjusted
model restricting the analysis to swab specimens with detected
HSV-2 collected from participants reporting 190% adherence
to the treatment regimen, as measured by average adherence
in the preceding quarter ( swab specimens), the meannp 627
reduction in the log10 HSV DNA copy count increased mar-
ginally in all groups, but regional differences persisted (1.31
log10 HSV DNA copy reduction in the US MSM, 0.89 in the
Peruvian MSM, and 0.47 in the African women; forPp .30
the difference between regions).
Discussion. In this large, multisite, international trial of
suppressive HSV-2 therapy, the standard dose of twice daily
acyclovir reduced the incidence of GUD recurrence by half
overall, reduced the incidence of ulcers with detectable HSV-
2 by 63%, and reduced the HSV DNA copy count in samples
BRIEF REPORT • JID 2010:201 (15 April) • 1167
from those ulcers by 0.43 log10 copies. However, we observed
significant regional variation in the incidence of GUD diagnosis
on examination, as well as the frequency and amount of HSV
detected in specimens from ulcers in US and Peruvian MSM
and African women. These differences by region in the quantity
of HSV-2 detected in swab specimens from genital herpes le-
sions persisted after adjusting for level of adherence to antiviral
therapy in the preceding quarter, and thus they are unlikely to
be explained by inadequate drug intake. Other possible expla-
nations for the lower efficacy of acyclovir on GUD-associated
HSV-2 shedding in populations outside the United States, par-
ticularly in Africa, include strain variation, resulting in inher-
ent acyclovir resistance among HSV strains from Africa, or un-
appreciated differences in acyclovir absorption or pharmaco-
kinetics. Detailed studies with frequent assessment of genital
shedding combined with drug level evaluation may elucidate
the mechanism underlying our observations.
The substantial body of evidence establishing the efficacy of
acyclovir suppression on clinical and subclinical HSV shedding
comes from studies of US and European cohorts [8, 9]. For
example, a recent study by Gupta and colleagues [10] that
enrolled men and women at research clinics in the Northwest
United States observed a 1.2–1.6 log10 reduction in HSV DNA
copy number by means of PCR in a comparison of acyclovir
and valacyclovir with placebo; this result mirrors our estimates
for US participants. Despite increased use of acyclovir world-
wide for syndromic management of HSV-2, data are limited
on the efficacy of suppressive HSV therapy in resource-poor
settings. However, over the past several years, studies in Peru
[11] and Africa [12] evaluating HSV-2 suppression with both
drugs to reduce HIV shedding and disease progression among
HIV-infected men and women have also shown efficacy in re-
ducing HSV-2 viral shedding, on the basis of molecular diag-
nostic methods similar to those used in the present study. The
authors of the Tanzanian trial [4] suggested that suboptimal
adherence to a regimen of 400 mg of acyclovir twice daily may
account for the lack of efficacy in reducing the incidence of
HIV acquisition among the HIV-negative women enrolled in
their study, as evidenced by a lower than anticipated reduction
in HSV shedding from cervicovaginal lavage specimens. How-
ever, in our study, adherence rates, measured primarily by pill
count, were 190% on average [3]. Moreover, our GUD analysis
showed only marginal improvements in the reduction of HSV
shedding across all groups when the analysis was restricted to
those with the highest level of adherence.
A limitation of this analysis is that we did not perform HSV
cultures at the time of GUD swab sampling, which would have
permitted us to phenotype viral isolates for acyclovir sensitivity,
nor did we perform genotypic assays to determine whether pop-
ulations outside the United States had a greater prevalence of
acyclovir resistance, although future studies are planned. Given
that acyclovir resistance is infrequent among immunocompetent
persons from settings with high levels of background acyclovir
use [13], it is unlikely that resistance from this mechanism would
be observed in Peru and Africa, where acyclovir availability re-
mains very limited.
Regional differences in HSV-2 shedding, despite suppressive
therapy, were unexpected and may have several implications.
Potential biological explanations require further exploration to
assess differential effects of acyclovir by population. Thus far,
liquid chromatography performed on study drug stored in the
field has confirmed expected drug potency [3], and studies are
currently underway to assess pharmacokinetics and GUD heal-
ing among African women treated with standard episodic acy-
clovir dosing. In addition, HSV-2 genotypic strain variation has
been reported [14], and although an association with lower
susceptibility to acyclovir has not been observed, further study
of viral polymorphisms as a potential explanation for the re-
gional differences in acyclovir response is warranted. Of note,
although our study relied on pill count and self-report to mea-
sure adherence to the study regimen, as is the standard for most
biomedical prevention trials, these methods may overestimate
adherence [15]. Finally, efforts to identify a safe and effective
HSV-2 vaccine must continue, to reduce the burden of new
HSV-2 infections globally and potentially reduce HIV trans-
mission risk in those regions most affected by the epidemic.
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